Multiple Myeloma Hub | Quarter Three 2019 Update

The Multiple Myeloma (MM) Hub continues to disseminate the latest clinical updates in MM.

Guided by an international Steering Committee of world experts in MM, the MM Hub is a global online resource that provides vital information for treatment teams, and is run in collaboration with the European School of Haematology (ESH). With an ever-expanding social media presence, the aim of the MM Hub is to engage with the global community on all major social media platforms to impact real-world clinical practice.

The MM Hub is designed to deliver upon an unmet clinical need for targeted medical updates, to help treatment teams involved in MM care make informed therapeutic decisions. Last quarter, the MM Hub introduced new monthly educational themes showcasing content relating to hot topics in MM. Themes so far include; smoldering MM, patient-reported outcomes and measurable residual disease (MRD). These themes were infused with the latest clinical and translational insights gathered during the seventh annual meeting of the Society of Hematologic Oncology (SOHO) in Houston, US and the 17^th International Myeloma Workshop (IMW) in Boston, US.

The MM Hub showcases unbiased and credible evidence-based literature, drug approvals, case studies, international congress coverage and expert opinions, delivered by Scientific Education Support (SES).

SES love nothing more than building communities and networks to enhance the level of collective knowledge, using multichannel communications to disseminate medical advances.

The MM Hub would like to thank our Silver supporter Janssen Oncology, Bronze supporter Amgen and Contributor GSK for their continued support of the initiative. This year, the MM Hub is proud to announce Karyopharm, as a new Contributor of the MM Hub.

For more information on the MM Hub, please visit: www.multiplemyelomahub.com. For media enquiries, or to explore collaboration opportunities, please contact: secretariat@scientificeducationsupport.com.